Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. National Cancer Institute, Cancer Therapy Evaluation Program
EIR
•National Cancer Institute, Cancer Therapy Evaluation Program•July 17, 2014

National Cancer Institute, Cancer Therapy Evaluation Program – FDA EIR, Jul 17, 2014

Record Details

The FDA inspected the National Cancer Institute, Cancer Therapy Evaluation Program (NCI, CTEP) from June 16 to July 17, 2014, in their capacity as a clinical trial sponsor for BLA No. 125516, involving protocol ANBL0032. The inspection, conducted under regulations governing clinical trial sponsors, identified multiple compliance issues. Primary violations included a failure to provide a comprehensive list of all investigators involved in the study and selecting unqualified or unregistered personnel, such as a physician who co-consented a patient without proper registration or an FDA-1572 form. The trial monitoring was deemed inadequate, with 22 of 163 sites not having patient cases reviewed, on-site audits occurring only every three to four years, and a limited scope of patient case review. Additionally, financial disclosure documents were not consistently collected from all investigators, and the program had delayed implementing financial disclosure requirements. Issues with electronic records included unvalidated data systems and randomization algorithms. NCI, CTEP submitted a written response, proposing a new centralized system to track investigators, but specific corrective actions for the ANBL0032 study findings were not detailed.

Company
National Cancer Institute, Cancer Therapy Evaluation Program
Inspection date
July 17, 2014
Product type
Biologics
Office
Center for Drug Evaluation and Research
People
  • Karen Said (company_representative)
  • L Mary Smith (company_representative)
  • Jody Cleveland (company_representative)
  • Steven Friedman (company_representative)
  • Todd Alonzo (company_representative)
View Company Profile

ID · 0ea41923-e58e-4119-93c8-059ec001ad62

Violation Codes8
21 CFR 312.53(c)(1)(viii)21.U.S.C. 355(a)21 CFR 312.53(c)(4)21 CFR 21121 CFR 312.53(a)21 CFR 312.53(c)(1)21 CFR 312.56(a)21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for National Cancer Institute, Cancer Therapy Evaluation Program
  • 483 - 2014-07-17July 17, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore National Cancer Institute, Cancer Therapy Evaluation Program
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.